Evidence map›Paper›PMID 39289715›Full record

ArticleMalaria journal2024

Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Arba Minch Zuria District, Gamo Zone, Southwest Ethiopia.

Demeke Daka, Daniel Woldeyes, Lemu Golassa, Gezahegn Solomon Alemayehu, Zerihun Zewde, Girum Tamiru, Tadesse Misganaw, Fekadu Massebo, Biniam Wondale

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Artemisinin resistantmedRxiv : the preprint server for health sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Demeke DakaDepartment of Biology, Arba Minch University, Arba Minch, Ethiopia.
Daniel WoldeyesDepartment of Biology, Arba Minch University, Arba Minch, Ethiopia.
Lemu GolassaAklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Gezahegn Solomon AlemayehuEthiopian Defence University College of Health Sciences, Bishoftu, Ethiopia.
Zerihun ZewdeArba Minch Public Health Laboratory, South Ethiopia Region Public Health Institute, Arba Minch, Ethiopia.
Girum TamiruDepartment of Biology, Arba Minch University, Arba Minch, Ethiopia.
Tadesse MisganawDepartment of Medical Laboratory Science, Woldia University, Woldia, Ethiopia.
Fekadu MasseboDepartment of Biology, Arba Minch University, Arba Minch, Ethiopia.
Biniam WondaleDepartment of Biology, Arba Minch University, Arba Minch, Ethiopia. biniamw2005@yahoo.com.

Funding

Norwegian Programme for Capacity Development in Higher Education and Research ETH-13/0025
6 · The paper itself

Abstract

backgroundArtemether-lumefantrine (AL) has been the primary anti-malarial drug used to treat uncomplicated Plasmodium falciparum malaria in Ethiopia since 2004. However, there have been recent reports of AL resistance mutations in different African countries, including Ethiopia. This is concerning and requires periodic monitoring of anti-malarial drug resistance. Therefore, the current study aimed to evaluate the therapeutic efficacy of AL in treating uncomplicated P. falciparum malaria in the Arba Minch Zuria District, Gamo Zone, Southwest Ethiopia.

methodsA single-arm prospective study with a 28-day follow-up period was conducted from July to October 2022. Capillary blood samples were collected for RDT and microscopic examination. The study enrolled monoinfected P. falciparum patients aged ≥ 18 years at Ganta Sira Health Post. Sociodemographic and clinical data were recorded, and a dried blood spot (DBS) was prepared for each participant. Nested polymerase chain reaction (nPCR) genotyping of the msp-1 and msp-2 genes was only performed for recurrent cases to distinguish between recurrence and reinfection. Data entry and analysis were performed using the WHO Excel spreadsheet and SPSS version 26.

resultsA total of 89 patients were enrolled, and 67 adequately completed the 28-day follow-up period. AL showed a 100% clearance rate for fever on day 2 and asexual parasites on day 3. Gametocytes were detected in 13.5% (12/89) of the participants. The gametocyte clearance rate was 58.3% (7/12) until day 7 and 100% (12/12) until day 14. Five participants developed recurrent malaria, three of whom experienced relapse and two of whom experienced reinfection. Based on the Kaplan-Meier survival analysis, the PCR-uncorrected and PCR-corrected cumulative incidence of success were 93.7% (95% CI 85.5-97.3) and 96.2% (95% CI 85.5-98.7), respectively.

conclusionAL was efficacious in treating uncomplicated P. falciparum malaria in the study area. However, the detection of recurrent patients highlights the need for continuous efficacy studies in this area.

Indexed as

AntimalarialsArtemether, Lumefantrine Drug CombinationMalaria, FalciparumPlasmodium falciparumAdolescentAdultAgedAntigens, ProtozoanEthiopiaFemaleHumansMaleMerozoite Surface Protein 1Middle AgedProspective StudiesProtozoan ProteinsAntigens, ProtozoanAntimalarialsArtemether, Lumefantrine Drug CombinationMerozoite Surface Protein 1merozoite surface protein 2, PlasmodiumProtozoan ProteinsCure rateMalariaParasite clearanceRecurrence

Identifiers

PMID39289715
PMCPMC11406784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.